1-2 of 2
Agnieszka Jozwik
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

Open Access
Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, Maria Almena-Carrasco, Agnieszka Jozwik, Sylvain Fouliard, Yasmina Adimy, Julia Geronimi, Charlotte Graham, Nitin Jain, Marcela V. Maus, Mohamad Mohty, Nicolas Boissel, Takanori Teshima, Koji Kato, Reuben Benjamin, Svetlana Balandraud
Journal: Cancer Research Communications
Cancer Research Communications (2022) 2 (11): 1520–1531.
https://doi.org/10.1158/2767-9764.CRC-22-0175
Published: 30 November 2022
View articletitled, Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Open the PDF for Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Open Access
Ana M. Metelo, Agnieszka Jozwik, Le Anh Luong, Delaney Dominey-Foy, Charlotte Graham, Charlotte Attwood, Shafqat Inam, Alan Dunlop, Katy Sanchez, Kirsty Cuthill, Carmel Rice, Matthew Streetly, Trevor Bentley, Bijan Boldajipour, Cesar Sommer, Barbra Sasu, Reuben Benjamin
Journal: Cancer Research Communications
Cancer Research Communications (2022) 2 (3): 158–171.
https://doi.org/10.1158/2767-9764.CRC-21-0157
Published: 23 March 2022
View articletitled, Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Open the PDF for Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors in another window